逆行开放肠系膜支架置入术治疗肠系膜缺血的临床中期结局
单中心回顾性分析2007至2020年34例接受逆行开放肠系膜支架置入术(ROMS)的肠系膜缺血患者,技术成功率91%,30天死亡率35%且均见于急性或慢加急性缺血患者。中位随访3.7年,1年和3年一期通畅率分别为70%和61%,免于症状复发率均为95%。
要点
- ROMS技术成功率91%,覆盖支架使用率64%,30天死亡率35%且全部见于急性或慢加急性缺血患者。
- 中位随访3.7年,1年和3年一期通畅率分别为70%和61%,免于再干预率分别为87%和71%。
- 1年和3年免于症状复发率均为95%,出院后再干预均为腔内方式,无中转旁路手术。
核心结论
- ROMS在肠系膜缺血患者中技术成功率高,尽管慢性动脉粥样硬化负担重。
- 中期通畅率可接受,但急性肠系膜缺血仍伴随高早期并发症和死亡率,以及高相关肠切除率。
- ROMS是血管外科医生治疗武器库中有价值的工具。
研究设计与样本
- 单中心回顾性综述,纳入2007年至2020年接受ROMS的患者。
- 共34例患者,19例女性(56%),平均年龄71±10岁。
- 终点包括并发症和死亡率、技术成功、一期通畅率、再干预和免于临床复发。
主要发现
- 18例(53%)表现为急性肠系膜缺血,11例(32%)为慢加急性,5例(15%)为慢性肠系膜缺血。
- 病因:28例(82%)为慢性动脉粥样硬化伴或不伴原位血栓形成,3例为肠系膜上动脉夹层,栓塞性、血管炎性和非闭塞性缺血各1例。
- 技术成功(定义为经逆行途径成功置入支架)31例(91%),其余3例分别接受经肱动脉支架置入2例和髂肠系膜旁路1例。
- 30天死亡率35%,全部为急性肠系膜缺血(10例)或慢加急性(2例)患者;18例(53%)接受肠切除,均为急性表现者。
- 中位随访3.7年(四分位距:0.8-5.0年),出院存活患者中5例需再干预,1年和3年免于再干预率分别为87%和71%。
关键数值与推荐
- 技术成功率为91%(31/34)。
- 30天死亡率为35%,全部见于急性肠系膜缺血(10例)或慢加急性(2例)患者。
- 1年和3年一期通畅率分别为70%和61%;1年和3年一期辅助通畅率87%,1年和3年二期通畅率97%。
- 1年和3年免于症状复发率均为95%。
- 1年和3年免于再干预率分别为87%和71%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrograde open mesenteric stenting (ROMS) has become a mainstay in treatment of mesenteric ischemia; however, follow-up in contemporary studies is limited. METHODS: A single-center retrospective review of patients undergoing ROMS from 2007 to 2020 was conducted. Demographics, presentation, and procedural details were reviewed. End points were morbidity and mortality, technical success, primary patency, reinterventions, and freedom from clinical recurrence. RESULTS: ROMS was performed in 34 patients, 19 female (56%). Mean age was 71 ± 10 years. Eighteen patients (53%) presented with acute mesenteric ischemia (AMI), 11 (32%) with acute-on-chronic, and 5 (15%) with chronic mesenteric ischemia. Etiology was chronic atherosclerosis with/without in-situ thrombosis in 28 patients (82%), superior mesenteric artery dissection in 3, and 1 each with embolic, vasculitic, and nonocclusive ischemia. Four patients (12%) had prior mesenteric procedures (3 Celiac/1 superior mesenteric artery stent) and 1 had unsuccessful transbrachial stenting attempt. Technical success, defined as successful stenting through a retrograde approach was attained in 31 patients (91%), with the 3 remaining patients treated with transbrachial stenting in 2 and iliomesenteric bypass in 1. Covered stents were used in 21 patients (64%) with or without stent extension with bare-metal stents. Eight patients (23%) required thromboembolectomy and 9 (26%) underwent patch angioplasty. Thirty-day mortality rate was 35%, all in patients with AMI (10) or acute-on-chronic (2). Eighteen patients (53%) underwent bowel resection, all presenting acutely. Early reinterventions within the first 30 days were required in 5 patients (15%), including 2 redo ROMS with thrombectomy and endarterectomy, 2 percutaneous stent extensions, and 1 aortic septum fenestration with coiling of a jejunal branch pseudoaneurysm. With a median follow-up of 3.7 (interquartile range: 0.8-5.0) years, in patients surviving discharge, 5 required reintervention yielding freedom from reintervention rates of 87% at 1 year and 71% at 3 years. All postdischarge reinterventions were endovascular with no conversion to bypass. The overall 1-year and 3-year primary patency rates were 70% and 61% (primary-assisted patency at 1 and 3 years was 87% and secondary patency at 1 and 3 years was 97%). The freedom from symptom recurrence was 95% at 1 and 3 years. CONCLUSIONS: ROMS carries high rates of technical success in patients with mesenteric ischemia, despite a high chronic atherosclerotic burden. Although mid-term patency rates are acceptable, AMI is still associated with high early morbidity and mortality, with high rates of associated bowel resection. ROMS is a valuable tool in the armamentarium of vascular surgeons.
引用
- Cirillo-Penn NC, DeMartino RR, Rasmussen TE, et al. Midterm Clinical Outcomes of Retrograde Open Mesenteric Stenting for Mesenteric Ischemia. Ann Vasc Surg. 2022. PMID: 36404451. doi:10.1016/j.avsg.2022.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。